In the last trading session, 4.17 million shares of the Nuvation Bio Inc (NYSE:NUVB) were traded, and its beta was 1.42. Most recently the company’s share price was $2.24, and it changed around -$0.06 or -2.61% from the last close, which brings the market valuation of the company to $762.18M. NUVB currently trades at a discount to its 52-week high of $3.97, offering almost -77.23% off that amount. The share price’s 52-week low was $1.54, which indicates that the current value has risen by an impressive 31.25% since then. We note from Nuvation Bio Inc’s average daily trading volume that its 10-day average is 3.92 million shares, with the 3-month average coming to 3.27 million.
Nuvation Bio Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended NUVB as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Nuvation Bio Inc is expected to report earnings per share of -0.14 for the current quarter.
Nuvation Bio Inc (NYSE:NUVB) trade information
Instantly NUVB has showed a red trend with a performance of -2.61% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.41 on recent trading dayincreased the stock’s daily price by 7.05%. The company’s shares are currently down -15.79% year-to-date, but still down -2.61% over the last five days. On the other hand, Nuvation Bio Inc (NYSE:NUVB) is 5.16% up in the 30-day period. We can see from the shorts that 33.1 million shares have been sold at a short interest cover period of 10.02 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 62.67% from its current value. Analyst projections state that NUVB is forecast to be at a low of $6 and a high of $6.
Nuvation Bio Inc (NUVB) estimates and forecasts
The year-over-year growth rate is expected to be 97.19%, up from the previous year.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of 416.67k in revenue for the current quarter. 6 analysts expect Nuvation Bio Inc to make 3.1M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.44M and 727k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -70.96%. Forecasts for the next quarter put sales growth at 326.41%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -49.14%. Nuvation Bio Inc earnings are expected to increase by 69.68% in 2025, but the outlook is positive 37.79% per year for the next five years.
NUVB Dividends
Nuvation Bio Inc’s next quarterly earnings report is expected to be released on 2025-May-06.
Nuvation Bio Inc (NYSE:NUVB)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 19.12% of Nuvation Bio Inc shares, and 61.77% of them are in the hands of institutional investors. The stock currently has a share float of 76.38%. Nuvation Bio Inc stock is held by 210.0 institutions, with FMR LLC being the largest institutional investor. By 2024-06-30, it held 11.7767% of the shares, which is about 28.82 million shares worth $84.16 million.
ECOR1 CAPITAL, LLC, with 7.8491% or 19.21 million shares worth $56.09 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 15.47 shares worth $34.64 million, making up 4.55% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 8.96 shares worth around $20.07 million, which represents about 2.63% of the total shares outstanding.
